GlaxoSmithKline News and Research

RSS

Sermo Category Report: About 30% of patients suffer from depression

Sermo, the world's largest online community for physicians, today announced a Sermo Category Report titled Antidepressant Treatment Behaviors. The report surveyed more than 200 primary care physicians and covers a variety of topics including product choice drivers, treatment paths, referring habits, and overall issues in depression management.

6 May 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2010, and company highlights.

6 May 2010

Families need to achieve optimal oral health: New study

According to a new study surveying U.S. moms, a significant majority (69 percent) feel meeting the specific oral health care needs of each family member is very important, however, nearly half of moms (48 percent) report using a "one size fits all" approach when it comes to oral health care products in their home.

5 May 2010

Fate of the unused swine flu vaccines

The United States Government in an announcement on Monday revealed that the U.S. still has 71 million doses of unused H1N1 swine flu vaccine but there is still time left before it is wasted. They have urged the providers to keep the vaccines and continue to supply them to people until pharmaceutical manufacturers start distributing seasonal vaccine for the coming influenza season in the autumn.

4 May 2010

FDA critics say controversy about diabetes drug points to need for agency changes

Reuters: "The controversy surrounding a GlaxoSmithKline Plc diabetes drug points to a need for changes in the way the U.S. Food and Drug Administration handles safety issues, agency critics told lawmakers on Wednesday.

30 Apr 2010

FDA approves Provenge prostate cancer vaccine

Cancer may now be fought with a vaccine. The FDA has finally approved an immune boosting vaccine which is said to extend survival of patients at an advanced stage of prostate cancer by four months. This is twice as long as what could be expected with regular chemotherapy. There is also an increase of three years survival after detection in initial stage by 38% thanks to the vaccine.

30 Apr 2010

Neurocrine Biosciences reports net loss of $8.6M in first quarter 2010

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $8.6 million, or $0.19 per share compared with a net loss of $19.7 million, or $0.51 per share, for the same period in 2009.

29 Apr 2010

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

Seattle Genetics, Inc. today reported financial results for the first quarter ended March 31, 2010. The company also highlighted recent product development activities and planned milestones.

28 Apr 2010

Advair to remain favored fixed-dose LABA/ICS combination therapy through 2013 for asthma and COPD

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite increased competition from several emerging agents, GlaxoSmithKline's Advair will remain surveyed pulmonologists' and primary care physicians' (PCPs) favored fixed-dose long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination inhaler through 2013 for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

27 Apr 2010

SuperGen's total revenues for 2010 first-quarter increased to $14.4M

SuperGen, Inc. today reported financial results for the first quarter ended March 31, 2010.

27 Apr 2010

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.

26 Apr 2010

Intellect Neurosciences completes restructuring of balance sheet

Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease, announced today it has completed a restructuring of its balance sheet. The result is the extinguishment of approximately $24 million of aggregate face amount plus accrued interest of debt and preferred stock through the issuance of common stock.

26 Apr 2010

AFFiRiS' AD02 Alzheimer's vaccine candidate in phase II clinical testing

AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the corresponding phase I study. The company is active in several disease areas and is currently developing a total of twelve prospective products in all stages of the development pipeline up to clinical phase II.

24 Apr 2010

North Carolina GlaxoSmithKline Foundation awards $25,000 grants to 9 nonprofits

The North Carolina GlaxoSmithKline Foundation announced that it has awarded $25,000 grants to nine nonprofits this year, around the state to support activities that establish or expand programs that further science, education and health in local communities.

23 Apr 2010

Genmab reaches milestone for Arzerra under terms of collaboration with GSK

Genmab A/S announced today it has reached a milestone for Arzerra(ofatumumab) under the terms of its collaboration with GlaxoSmithKline.

23 Apr 2010

Swine flu vaccine blues

Exactly a year after the swine flu outbreak vigilance, newer vaccine techniques and other measures are being emphasized by researchers and key decision makers. Dr. Harvey Fineberg, chairman of the World Health Organization's pandemic review committee and President of the U.S. Institute of Medicine says, we need to look at the past to learn from it.

22 Apr 2010

Positive results from pivotal Phase 3 trials of BENLYSTA in SLE patients

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced topline secondary endpoints from BLISS-76, the second of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus.

20 Apr 2010

Biovest to make presentation on BiovaxID cancer vaccine at World Vaccine Congress 2010

Biovest International, Inc. today announced that the Company will be making a presentation regarding its personalized cancer vaccine, BiovaxID, on April 22 at the World Vaccine Congress which is currently ongoing in Washington D.C.

20 Apr 2010

Global Leaders Institute to host VacChina 2010 Vaccine Development Summit

Hosted by Global Leaders Institute, "VacChina 2010", a Vaccine Development Summit to be held from September 15-16, 2010, will bring together the world's major vaccine players and their respective senior level representatives to Shanghai, the heart of China's biopharmaceutical innovation.

17 Apr 2010

Sunlight Research's Stem Cell Industry Report analyzes U.S. Stem Cell patent landscape

Sunlight Research – The Source for Patent Analysis, today announced the release of its comprehensive Stem Cell Industry Report analyzing the U.S. Stem Cell patent landscape. Stem cells are particularly attractive for use as cellular therapies because they self-renew and have the capacity to produce many different specialized cell types.

16 Apr 2010